[1] | Agca R, Blanken AB, van Sijl AM, Smulders YM, Voskuyl AE, van der Laken C, et al. Arterial wall inflammation is increased in rheumatoid arthritis compared with osteoarthritis, as a marker of early atherosclerosis. Rheumatol (Oxford) (2021) 60(7): 3360–8. doi:10.1093/rheumatology/keaa789. |
[2] | Amaya-Amaya J, Montoya-Sánchez L, Rojas-Villarraga A. Cardiovascular involvement in autoimmune diseases. BioMed Res Int (2014) 2014: 367359. doi:10.1155/2014/367359. |
[3] | Blum A, Adawi M. Rheumatoid arthritis (RA) and cardiovascular disease. Autoimmun Rev (2019) 18(7): 679–90. doi:10.1016/j.autrev.2019.05.005. |
[4] | Błyszczuk P, Szekanecz Z. Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis. RMD Open (2020) 6(1): e001032. doi:10.1136/rmdopen-2019-001032. |
[5] | Buckley LF, Abbate A. Interleukin-1 blockade in cardiovascular diseases: a clinical update.Eur Heart J(2018) 39(22): 2063–9. doi:10.1093/eurheartj/ehy128. |
[6] | Castañeda S, González-Juanatey C, González-Gay MA. Sex and cardiovascular involvement in inflammatory joint diseases. Clin Rev Allergy Immunol (2019) 56(3): 278–92. doi:10.1007/s12016-017-8635-2. |
[7] | Cavalli G, Favalli EG. Cardiovascular disease in patients with rheumatoid arthritis: impact of classic and disease-specific risk factors.Ann Transl Med(2018) 6 (Suppl 1): S82. doi:10.21037/atm.2018.10.72. |
[8] | Chen J, Norling LV, Cooper D. Cardiac dysfunction in rheumatoid arthritis: The role of inflammation. Cells (2021) 10(4): 881. doi:10.3390/cells10040881. |
[9] | Conforti A, Di Cola I, Pavlych V, Ruscitti P, Berardicurti O, Ursini F, et al. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun Rev (2021) 20(2): 102735. doi:10.1016/j.autrev.2020.102735. |
[10] | da Fonseca LJS, Nunes-Souza V, Goulart MOF, Rabelo LA. Oxidative stress in rheumatoid arthritis: what the future might hold regarding novel biomarkers and add-on therapies. Oxid Med Cell Longevity (2019) 2019 (7): 16. doi: 10.1155/2019/7536805.7536805. |
[11] | Darrah E, Andrade F. Rheumatoid arthritis and citrullination. Curr Opin Rheumatol (2018) 30(1): 72–8. doi:10.1097/BOR.0000000000000452. |
[12] | Davies R, Williams J, Sime K, Jin HS, Thompson C, Jordan L, et al. The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis. Rheumatology (2021) 60: 2852–61. doi:10.1093/rheumatology/keaa725. |
[13] | DeMizio DJ, Geraldino-Pardilla LB. Autoimmunity and inflammation link to cardiovascular disease risk in rheumatoid arthritis. Rheumatol Ther (2020) 7 (1): 19–33. doi:10.1007/s40744-019-00189-0. |
[14] | Derksen VFAM, Huizinga TWJ, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol (2017) 39(4): 437–46. doi:10.1007/s00281-017-0627-z. |
[15] | Dijkshoorn B, Raadsen R, Nurmohamed MT. Cardiovascular disease risk in rheumatoid arthritis anno 2022. J Clin Med (2022) 11(10): 2704. doi: 10.3390/jcm11102704. |
[16] | Ferreira MB, Fonseca T, Costa R, Marinhoc A, Carvalho HC, Oliveira JC, et al. Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study. Eur J Intern Med (2021) 85: 41–9. doi:10.1016/j.ejim.2020.11.002. |
[17] | Giles JT. Extra-articular manifestations and comorbidity in rheumatoid arthritis: Potential impact of pre-rheumatoid arthritis prevention. Clin Ther(2019) 41(7): 1246–55. doi:10.1016/j.clinthera.2019.04.018. |
[18] | Hermans MPJ, van der Velden D, Montero Cabezas JM, Putter H, Huizinga TWJ, Kuiper J, et al. Long-term mortality in patients with ST-segment elevation myocardial infarction is associated with anti-citrullinated protein antibodies.Int J Cardiol (2017) 240: 20–4. doi:10.1016/j.ijcard.2017.04.046. |
[19] | Hu Q, Ecker M. Overview of MMP-13 as a promising target for the treatment of osteoarthritis.Int J Mol Sci (2021) 22(4): 1742. doi:10.3390/ijms22041742. |
[20] | Hu XX, Wu YJ, Zhang J, Wei W. T-Cells interact with b cells, dendritic cells, andfibroblast-like synoviocytes as hub-like key cells in rheumatoid arthritis. Int Immunopharmacol (2019) 70:428–34. doi:10.1016/j.intimp.2019.03.008. |
[21] | Jamthikar AD, Gupta D, Puvvula A, Johri AM, Khanna NN, Saba L, et al. Cardiovascular risk assessment in patients with rheumatoid arthritis using carotid ultrasound b-mode imaging. Rheumatol Int (2020) 40(12): 1921–39. doi:10.1007/s00296-020-04691-5. |
[22] | Juarez M, Bang H, Hammar F, Reimer U, Dyke B, Sahbudin I, et al. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum Dis (2016) 75(6): 1099–107. doi: 10.1136/annrheumdis-2014-206785. |
[23] | Køster D, Egedal JH, Lomholt S, Hvid M, Jakobsen MR, Müller-Ladner U, et al. Phenotypic and functional characterization of synovial fluid-derived fibroblast-like synoviocytes in rheumatoid arthritis. Sci Rep (2021) 11(1): 22168. doi:10.1038/s41598-021-01692-7. |
[24] | Kronzer VL, Crowson CS, Sparks JA, Myasoedova E, Davis JM3rd. Comorbidities as risk factors for rheumatoid arthritis and their accrual after diagnosis. Mayo Clin Proc(2019) 94(12): 2488–98. doi: 10.1016/j.mayocp.2019.08.010. |
[25] | Lin YJ, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells (2020) 9(4): 880. doi:10.3390/cells9040880. |
[26] | Maiuolo J, Muscoli C, Gliozzi M, Musolino V, Carresi C, Paone S, et al. Endothelial dysfunction and extra-articular neurological manifestations in rheumatoid arthritis. Biomolecules (2021) 11(1): 81. doi:10.3390/biom11010081. |
[27] | Makavos G, Varoudi M, Papangelopoulou K, Kapniari E, Plotas P, Ikonomidis I, et al. Echocardiography in autoimmune rheumatic diseases for diagnosis and prognosis of cardiovascular complications. Medicina (Kaunas) (2020) 56(9): 445. doi:10.3390/medicina56090445. |
[28] | Myasoedova E, Davis J, Matteson EL, Crowson CS. Is the epidemiology of rheumatoid arthritis changing? results from a population-based incidence study, 1985-2014. Ann Rheum Dis (2020) 79(4): 440–4. doi:10.1136/annrheumdis-2019-216694. |
[29] | Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, van der Goes MC, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis (2022) 81(1): 20–33. doi: 10.1136/annrheumdis-2021-220973. |
[30] | Nygaard G, Firestein GS. Restoring synovial homeostasis in rheumatoid arthritis by targetingfibroblast-like synoviocytes. Nat Rev Rheumatol (2020) 16 (6): 316–33. doi:10.1038/s41584-020-0413-5. |
[31] | Pascale V, Finelli R, Giannotti R, Coscioni E, Izzo R, Rozza F, et al. Cardiac eccentric remodeling in patients with rheumatoid arthritis. Sci Rep (2018) 8 (1): 5867. doi:10.1038/s41598-018-24323-0. |
[32] | Patel KHK, Jones TN, Sattler S, Mason JC, Ng FS. Proarrhythmic electrophysiological and structural remodeling in rheumatoid arthritis. Am J Physiol Heart Circ Physiol (2020) 319(5): H1008–20. doi:10.1152/ajpheart.00401.2020. |
[33] | Patel RB, Shah SJ. Drug targets for heart failure with preserved ejection fraction: A mechanistic approach and review of contemporary clinical trials. Annu Rev Pharmacol Toxicol (2019) 59: 41–63. doi:10.1146/annurev-pharmtox-010818-021136. |
[34] | Plastiras SC, Moutsopoulos HM. Arrhythmias and conduction disturbances in autoimmune rheumatic disorders. Arrhythm Electrophysiol Rev (2021) 10(1): 17–25. doi:10.15420/aer.2020.43. |
[35] | RezuşE, Macovei LA, Burlui AM, Cardoneanu A, RezuşC. Ischemic heart disease and rheumatoid arthritis-two conditions, the same background.Life (Basel) (2021) 11(10): 1042. doi:10.3390/life11101042. |
[36] | Salem HR, Zahran ES. Vascular cell adhesion molecule-1 in rheumatoid arthritis patients: Relation to disease activity, oxidative stress, and systemic inflammation. Saudi Med J (2021) 42: 620–8. doi:10.15537/smj.2021.42.6.20200753. |
[37] | Schwartz DM, Burma AM, Kitakule MM, Luo Y, Mehta NN. T Cells in autoimmunity-associated cardiovascular diseases. Front Immunol (2020) 11: 588776. doi:10.3389/fimmu.2020.588776. |
[38] | Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet (2010) 376 (9746): 1094–108. doi:10.1016/S0140-6736(10)60826-4. |
[39] | Taylor PC, Atzeni F, Balsa A, Gossec L, Müller-Ladner U, Pope J. The key comorbidities in patients with rheumatoid arthritis: A narrative review.J Clin Med (2021) 10(3): 509. doi:10.3390/jcm10030509. |
[40] | Wang X, Fan D, Cao X, Ye Q, Wang Q, Zhang M, et al. The role of reactive oxygen species in the rheumatoid arthritis-associated synovial microenvironment. Antioxid (Basel) (2022) 11(6): 1153. doi:10.3390/antiox11061153. |
[41] | Wu R, Gao W, Yao K, Ge J. Roles of exosomes derived from immune cells in cardiovascular diseases. Front Immunol (2019) 10: 648. doi:10.3389/fimmu.2019.00648. |
[42] | Xia ZB, Meng FR, Fang YX, Wu X, Zhang CW, Liu Y, et al. Inhibition of NFkB signaling pathway induces apoptosis and suppresses proliferation and angiogenesis of humanfibroblast-like synovial cells in rheumatoid arthritis. Med (Baltimore) (2018) 97(23): e10920. doi:10.1097/MD.0000000000010920. |
[43] | Yoshitomi H. Regulation of immune responses and chronic inflammation by fibroblast-like synoviocytes. Front Immunol (2019) 10: 1395. doi: 10.3389/fimmu.2019.01395. |